consoliDateD financial stateMents consoliDateD stateMents of incoMe Astellas Pharma Inc. and Subsidiaries  For the years ended 31 March 2013 and 2014 Astellas Pharma Inc. and Subsidiaries  For the years ended 31 March 2013 and 2014 consoliDateD stateMents of coMprehensive incoMe (Millions of yen) (Millions of U.S. dollars) Note 2013 2014 2014 Sales 6 ¥ 981,899 ¥1,139,909 $11,067 Cost of sales (308,711) (330,628) (3,210) Gross profit 673,187 809,281 7,857 Selling, general and administrative expenses (318,943) (397,018) (3,855) Research and development expenses (159,094) (191,460) (1,859) Amortisation of intangible assets 17 (28,266) (36,000) (350) Share of profits of associates and joint ventures 1,137 1,451 14 Other income 7 2,862 11,582 112 Other expense 8 (49,291) (81,029) (787) Operating profit 121,593 116,806 1,134 Finance income 10 7,339 6,827 66 Finance expense 11 (1,816) (1,658) (16) Profit before tax 127,115 121,975 1,184 Income tax expense 12 (34,651) (31,100) (302) Profit for the year ¥ 92,464 ¥ 90,874 $ 882 Profit attributable to: Owners of the parent ¥ 92,464 ¥ 90,874 $ 882 (yen) (U.S. dollars) Earnings per share Basic 13 ¥ 40.27 ¥ 40.45 $ 0.39 Diluted 13 40.21 40.39 0.39 (Millions of yen) (Millions of U.S. dollars) Note 2013 2014 2014 Profit for the year ¥ 92,464 ¥ 90,874 $ 882 Other comprehensive income Items that will not be reclassified subsequently to profit or loss Remeasurements of defined benefit plans (5,049) 4,648 45 Total items that will not be reclassified subsequently to profit or loss (5,049) 4,648 45 Items that may be reclassified subsequently to profit or loss Foreign currency translation adjustments 14 67,659 80,001 777 Fair value movements on available-for-sale financial assets 14 3,273 6,588 64 Total items that may be reclassified subsequently to profit or loss 70,932 86,590 841 Other comprehensive income, net of tax 65,883 91,238 886 Total comprehensive income ¥158,347 ¥182,112 $1,768 Total comprehensive income attributable to: Owners of the parent ¥158,347 ¥182,112 $1,768 Financial Section Annual Report 2014 _  Astellas Pharma Inc.  103